Further, auranofin reduced mean bacterial load by 90% in the liver compared to a 70% reduction in animals treated with linezolid
Provides Cardiovascular Benefits (Anti-inflammatory) Clinical trials (e.g., SUSTAIN-6, SELECT) have shown semaglutide reduces the risk of major adverse cardiovascular events (heart attack, stroke, CV death) in people with type 2 diabetes and high cardiovascular risk
However, its important to be aware that overall demand will continue to exceed supply which means that some patients may still have difficulty filling Wegovy prescriptions. Supply is not the only factor limiting access to Wegovy and other obesity medications
For instance, semaglutide received FDA and EMA approval for cardiovascular risk reduction in patients with obesity in 2024, and Novo Nordisk are also targeting the use of semaglutide in patients with obesity-related heart failure and metabolic associated steatohepatitis (MASH, formerly known as fatty liver disease)
[2] Some state governments have passed laws removing restrictions on the use of marijuana for personal or medicinal reasons within the state